The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center is pleased to announce the fourth annual Cost-Effectiveness Analysis (CEA) Paper of the Year has been awarded to Dr. Michael Fairley and colleagues from Stanford University and the VA Palo Alto Health Care System.
Their paper, which was published in JAMA Psychiatry, was an economic modeling study examining the cost-effectiveness of treatments for opioid use disorder in the United States. The study found that all forms of medication-assisted treatment (i.e., methadone, buprenorphine, and naltrexone), with or without overdose education and naloxone distribution, contingency management, and psychotherapy, were associated with cost-saving reductions in morbidity and mortality compared with no treatment. The largest cost savings were associated with methadone plus contingency management.
Dr. Fairley’s paper was chosen from a competitive pool of high-quality submissions for its exemplary methodological quality and timeliness. Each paper underwent blinded review by CEVR faculty members, who evaluated the submissions for methodological quality, timeliness, and potential influence on policy or clinical decision-making. The three papers with the highest faculty ratings were then reviewed by CEVR’s CEA Registry Scientific Advisory Board using the same criteria.
The two other finalists included a cost-effectiveness analysis biosimilar infliximab in adults with Crohn’s disease and a cost-effectiveness modeling study comparing strategies for typhoid conjugate vaccine introduction in India.
- Hughes A, Marshall JK, Moretti ME, Ungar WJ. A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. J Can Assoc Gastroenterol. 2021;4(1):e1-e11.
- Ryckman T, Karthikeyan AS, Kumar D, Cao Y, Kang G, Goldhaber-Fiebert JD, John J, Lo NC, Andrews JR. Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study. J Infect Dis. 2021;224(Supple 5):S612-S624.
We are now accepting submissions for the 5th Annual Paper of the Year Award: Criteria for the 2022 CEVR cost-effectiveness analysis paper of the year